Navigation Links
RXi Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference
Date:11/27/2013

WESTBOROUGH, Mass., Nov. 27, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's Chief Development Officer, Dr. Pamela Pavco, will present at the Piper Jaffray 25th Annual Healthcare Conference on Wednesday, December 4, 2013 at 12:00 pm EST at The New York Palace Hotel in New York, NY.  Dr. Pavco will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.

(Logo:  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO )

The presentation will be available on the "Investors" section of the Company's website, www.rxipharma.com.  

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contacts

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 4, 2013
2. Unique Pharmaceuticals Applauds Passage of Drug Quality and Security Act
3. AcelRx Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
4. Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx and Earns $3 Million Milestone Payment From GSK
5. Isis Pharmaceuticals to Present at the 2013 Deutsche Bank BioFEST
6. Sitari Pharmaceuticals, First Company Launched Through Avalon Ventures-GlaxoSmithKline Collaboration, Raises up to $10 Million Series A Financing and R&D Support
7. DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
8. Isis Pharmaceuticals to Investigate a Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
9. Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
10. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
11. Actinium Pharmaceuticals To Present At The LD Micro Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 Information products ... metrics in Scopus , the world,s largest abstract ... access to comprehensive metrics for journals from over 5,000 publishers. The ... which journals to subscribe to and when to adjust a journal,s ... , , ...
(Date:12/8/2016)... ALBANY, New York , December 8, 2016 ... the global Diabetes Injection Pens Market is expected ... as compared to US$4.9 bn in 2015. Between the forecast ... to rise at a CAGR of 7.9%. The leading players ... Nordisk A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The ... ultimate weight loss and wellness program, at their world headquarters of Omni La Costa ... and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, or ...
(Date:12/8/2016)... ... , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services from ... Messina. , Among the recognitions, the American College of Surgeons' (ACS) named the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. ... advocates for the mass media launching of story movements to highlight what's most ... their unfortunate experiences; such a movement can generate the network power to improve ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial consulting services to residential and commercial clients in the northern Alabama ... support for Nobis Works. , Since 1977, Nobis Works has built a network ...
Breaking Medicine News(10 mins):